Ceftin generic approved
Executive Summary
FDA approves Ranbaxy's ANDA for 125 mg, 250 mg and 500 mg tablets of cefuroxime axetil Feb. 20. The approvals were cleared by FDA's denial of petitions for a stay of cefuroxime approvals filed by GlaxoSmithKline and PDI. "Ranbaxy has met its burden" to show that the partially crystalline cefuroxime axetil in its product is the 'same' as the amorphous cefuroxime axetil in GSK's Ceftin, FDA said. Patent infringement litigation brought in October 2000 continues over the 4,562,181 Ceftin patent (1"The Pink Sheet" Aug. 20, 2001, p. 17)...
You may also be interested in...
Ranbaxy prevails in Ceftin lawsuit
GlaxoSmithKline's Ceftin patent is valid but Ranbaxy's cefuroxime generic does not infringe, a Trenton, N.J. federal judge rules March 31 in an opinion filed under seal. Ranbaxy was the first Ceftin generic on the market in early 2002 (1"The Pink Sheet" Feb. 5, 2002, In Brief)...
Ranbaxy Generic Ceftin May Clear FDA After USP Monograph Revision
Ranbaxy expects an ANDA approval for its generic version of GlaxoSmithKline's Ceftin shortly after U.S. Pharmacopeia monograph revisions for cefuroxime axetil become effective on Sept. 30.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.